COCs Flashcards
Female reproductive cycle
Ovarian cycle:
Period/menstruation - days 1-7
Follicular phase - 1-14.
Ovulation - day 14
Luteal phase - 15-28
Identify the hormonal changes that occur during the female reproductive cycle
FSH - Starts high, dips across follicular phase, peaks at ovulation, drops across luteal phase.
Estrogen - Start low, rises to peak just before ovulation, drops before rising again during luteal phase.
LH - spikes only during ovulation.
Progesterone - low until rising during luteal phase.
Anatomy relating to hormone changes
Ovaries secrete estrogen, estrogen acts on the hypothalamus, hypothalamus releases GnRH, GnRH acts on pituitary, pituitary releases LH and FSH which both act on ovary.
Ovary releases follicle which collapses into itself to form corpus luteum.
Estrogen and progesterone are found in follicle, corpus luteum, or uterus lining.
Advantages of COCs
Regular, lighter, less painful periods
Choose when periods occur
Improve acne and menstrual disorders
Reduce risk of PID, anaemia, and cancer
Advantages of nuvaring
No daily tablets
Regular periods and can pick when
Woman inserts and removes
Same as COCs
Disadvantages of COCs
Efficacy affected by drugs, vomiting, and diarrhoea
Taken each day at same time
Cause spotting, N/V, breast enlargment, tenderness, headache, fluid retention, BP increase, mood changes, VTE
Increased risk of MI and stroke in smokers >35
Disadvantages of nuvaring
Requires monthly insertion and removal
Vaginal irritation, infection, or discharge
Ring can be expelled
Explain COCs and use
Oral pill containing estrogen and progestogen
Inhibit ovulation
Reduce receptivity of endometrium to implantation
Thicken cervical mucous to form barrier to sperm
COC Indications (5)
Contraception
Acne
Menstrual disorders
Endometriosis
PMS
COCs contraindications (7)
Breast cancer - hormone-sensitive, worsen prognosis
Migraine w/ aura
Migraine > 35 y/o
History of VTE
Smoker > 35 y/o - increased VTE and CVD risk
End organ damage
COCs cautions (8)
Diabetes - increased risk of thrombosis
BMI>30 - increased risk of VTE
Smoker < 35 y/o
Hypertension - avoid use if BP not controlled
Surgery - increased thromboembolism risk (stop 4 weeks before, and then restart >2 weeks after)
Pregnancy - theory risk w/ cyproterone-containing
Breastfeeding - estrogen decrease milk supply
Postpartum - don’t use for 21 days or 42 days if VTE risk
COCs ADR risk considerations
Tolerance develops in the first 3 months of use
Benefits often outweigh risks
- Prevention of pregnancy
- Reduced menstrual loss
- Reduced ovarian cysts risk
- Reduced PID risk
- Reduced ovarian and endometrial cancer for 15 yrs
Common COC ADR
Breakthrough bleeding on low dose
N/V - because of estrogen
Breast enlargement and tenderness
Headache
Mood changes
Libido changes
Increased BP
Fluid retention
Melasma (hyperpigmentation)
Acne
Thrush
Infrequent COC ADR
Contact lense intolerance
Rash
Hirsutism (facial hair)
Alopecia
Altered lipid profiles
Hyperinsulinaemia (levonorgestrel COCs)
Insulin resistance
Rare COC ADR
Allergy (urticaria, angioedema)
Hypertension
Stroke
VTE
Photosensitivity
Jaundice, pancreatitis, liver cancer
Cervical cancer - increased risk w/ increased use
Breast cancer
VTE risk
Highest risk in first year of COC use, peak 3 mths
Depends on dose, type, and risk factors
Non-PBS pills = risk increases